87 related articles for article (PubMed ID: 26618438)
1. High-risk centers and the benefits for lower-risk transplants.
Marmor S; Begun JW; Abraham J; Virnig BA
Am J Manag Care; 2015 Sep; 21(9):e509-18. PubMed ID: 26618438
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
4. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
[TBL] [Abstract][Full Text] [Related]
5. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
8. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
[TBL] [Abstract][Full Text] [Related]
9. Severe sepsis in hematopoietic stem cell transplant recipients*.
Kumar G; Ahmad S; Taneja A; Patel J; Guddati AK; Nanchal R;
Crit Care Med; 2015 Feb; 43(2):411-21. PubMed ID: 25599465
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?
Ganly P; Cole S; Trengrove A; Butler A
Intern Med J; 2014 Jul; 44(7):683-9. PubMed ID: 24750295
[TBL] [Abstract][Full Text] [Related]
11. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.
Hoffmeister PA; Storer BE; Macris PC; Carpenter PA; Baker KS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1081-6. PubMed ID: 23623893
[TBL] [Abstract][Full Text] [Related]
12. Urinary elafin and kidney injury in hematopoietic cell transplant recipients.
Hingorani S; Finn LS; Pao E; Lawler R; Schoch G; McDonald GB; Najafian B; Sandmaier B; Gooley T
Clin J Am Soc Nephrol; 2015 Jan; 10(1):12-20. PubMed ID: 25388519
[TBL] [Abstract][Full Text] [Related]
13. Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation.
Hahn T; Sucheston-Campbell LE; Preus L; Zhu X; Hansen JA; Martin PJ; Yan L; Liu S; Spellman S; Tritchler D; Clay A; Onel K; Pasquini M; McCarthy PL
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1679-1686. PubMed ID: 26028504
[TBL] [Abstract][Full Text] [Related]
14. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center.
Fukuda T; Boeckh M; Guthrie KA; Mattson DK; Owens S; Wald A; Sandmaier BM; Corey L; Storb RF; Marr KA
Biol Blood Marrow Transplant; 2004 Jul; 10(7):494-503. PubMed ID: 15205670
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
16. The impact of center accreditation on hematopoietic cell transplantation (HCT).
Marmor S; Begun JW; Abraham J; Virnig BA
Bone Marrow Transplant; 2015 Jan; 50(1):87-94. PubMed ID: 25387091
[TBL] [Abstract][Full Text] [Related]
17. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant.
Wood W; Deal A; Whitley J; Sharf A; Serody J; Gabriel D; Shea T
Pediatr Blood Cancer; 2011 Sep; 57(3):499-505. PubMed ID: 21384538
[TBL] [Abstract][Full Text] [Related]
19. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients.
Goldberg SL; Klumpp TR; Magdalinski AJ; Mangan KF
J Clin Oncol; 1998 Dec; 16(12):3796-802. PubMed ID: 9850024
[TBL] [Abstract][Full Text] [Related]
20. Low volume is associated with worse patient outcomes for pediatric liver transplant centers.
Tracy ET; Bennett KM; Danko ME; Diesen DL; Westmoreland TJ; Kuo PC; Pappas TN; Rice HE; Scarborough JE
J Pediatr Surg; 2010 Jan; 45(1):108-13. PubMed ID: 20105589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
